Table 1.
Disease | Mutated gene | Functional deficit | Molecular targets |
---|---|---|---|
Dravet syndrome | SCN1A | Reduced excitability, reduced firing frequency | Voltage-gated sodium channels (activation) Glutamatergic synaptic transmission (potentiation) |
Episodic ataxia type 2 | CACNA1A | Irregular spiking, poor encoding of parallel fiber synaptic input | Calcium-activated potassium channels (activation) |
Huntington’s disease | HTT | Reduced firing frequency | – |
Spinocerebellar ataxia type 1 | ATXN1 | Reduced firing frequency | – |
Spinocerebellar ataxia type 2 | ATXN2 | Increased excitability, reduced firing frequency and bursting | Calcium-activated potassium channels (activation) |
Spinocerebellar ataxia type 3 | ATXN3 | Increased excitability, reducing firing frequency | Calcium-activated potassium channels (activation) |
Spinocerebellar ataxia type 5 | SPTNB2 | Reduced excitability, reduced firing frequency | Voltage-gated sodium channels (activation) Glutamatergic synaptic transmission (potentiation) FGF14/spectrin system (activation) |
Spinocerebellar ataxia type 27 | FGF14 | Reduced excitability, reduced firing frequency | Voltage-gated sodium channels (activation) Glutamatergic synaptic transmission (potentiation) FGF14/spectrin system (activation) |
List of dominantly inherited ataxic disorders where dysfunctional Purkinje neuron pacemaking has been described. The gene that is mutated in the disease, the nature of any deficits in Purkinje neuron pacemaking observed in these models and potential therapeutic targets for clinical intervention are outlined for each condition.